Dok Hyun Yoon

List of Publications by Year
in descending order

190 papers	2,919 citations	257450 24 h-index	254184 43 g-index
194 all docs	194 docs citations	194 times ranked	4384 citing authors

#	Article	IF	Citations
1	A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis. Lancet Oncology, The, 2016, 17, 389-400.	10.7	285
2	Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study. Journal of Clinical Oncology, 2022, 40, 481-491.	1.6	160
3	Incorporation of Immune Checkpoint Blockade into Chimeric Antigen Receptor T Cells (CAR-Ts): Combination or Built-In CAR-T. International Journal of Molecular Sciences, 2018, 19, 340.	4.1	157
4	ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma. Journal of Clinical Oncology, 2021, 39, 1317-1328.	1.6	132
5	Clinical Outcomes and Prognostic Factors of Up-Front Autologous Stem Cell Transplantation in Patients with Extranodal Natural Killer/T Cell Lymphoma. Biology of Blood and Marrow Transplantation, 2015, 21, 1597-1604.	2.0	76
6	Sorafenib for Recurrent Hepatocellular Carcinoma After Liver Transplantation. Japanese Journal of Clinical Oncology, 2010, 40, 768-773.	1.3	74
7	Phase 2 study of dovitinib in patients with metastatic or unresectable adenoid cystic carcinoma. Cancer, 2015, 121, 2612-2617.	4.1	63
8	Serum beta-2 microglobulin in malignant lymphomas: an old but powerful prognostic factor. Blood Research, 2014, 49, 148.	1.3	48
9	CD68 and CD163 as prognostic factors for Korean patients with Hodgkin lymphoma. European Journal of Haematology, 2012, 88, 292-305.	2.2	46
10	CD163 Expression Was Associated with Angiogenesis and Shortened Survival in Patients with Uniformly Treated Classical Hodgkin Lymphoma. PLoS ONE, 2014, 9, e87066.	2.5	46
11	Multicenter retrospective analysis of the clinicopathologic features of monomorphic epitheliotropic intestinal T-cell lymphoma. Annals of Hematology, 2019, 98, 2541-2550.	1.8	43
12	Daratumumab monotherapy for patients with relapsed or refractory natural killer/T-cell lymphoma, nasal type: an open-label, single-arm, multicenter, phase 2 study. Journal of Hematology and Oncology, 2021, 14, 25.	17.0	41
13	Programmed death 1 expression in the peritumoral microenvironment is associated with a poorer prognosis in classical Hodgkin lymphoma. Tumor Biology, 2016, 37, 7507-7514.	1.8	40
14	A Randomized Feasibility Study of ¹⁸F-Fluoroestradiol PET to Predict Pathologic Response to Neoadjuvant Therapy in Estrogen Receptorâ€“Rich Postmenopausal Breast Cancer. Journal of Nuclear Medicine, 2017, 58, 563-568.	5.0	40
15	Randomized Phase 2 Trial of S1 and Oxaliplatin-Based Chemoradiotherapy With or Without Induction Chemotherapy for Esophageal Cancer. International Journal of Radiation Oncology Biology Physics, 2015, 91, 489-496.	0.8	39
16	Higher infused CD34+ hematopoietic stem cell dose correlates with earlier lymphocyte recovery and better clinical outcome after autologous stem cell transplantation in nonâ€Hodgkin's lymphoma. Transfusion, 2009, 49, 1890-1900.	1.6	38
17	PD-L1 expression correlates with VEGF and microvessel density in patients with uniformly treated classical Hodgkin lymphoma. Annals of Hematology, 2017, 96, 1883-1890.	1.8	37
18	Mosunetuzumab, a Novel CD20/CD3 Bispecific Antibody, in Combination with CHOP Confers High Response Rates in Patients with Diffuse Large B-Cell Lymphoma. Blood, 2020, 136, 37-38.	1.4	37

#	Article	IF	Citations
19	Phase II trial of concurrent chemoradiotherapy with L-asparaginase and MIDLE chemotherapy for newly diagnosed stage I/II extranodal NK/T-cell lymphoma, nasal type (CISL-1008). Oncotarget, 2016, 7, 85584-85591.	1.8	36
20	Percutaneous Management of a Bronchobiliary Fistula after Radiofrequency Ablation in a Patient with Hepatocellular Carcinoma. Korean Journal of Radiology, 2009, 10, 411.	3.4	34
21	Kiâ€67 expression as a prognostic factor in diffuse large Bâ€cell lymphoma patients treated with rituximab plus CHOP. European Journal of Haematology, 2010, 85, 149-157.	2.2	34
22	Comprehensive evaluation of the revised international staging system in multiple myeloma patients treated with novel agents as a primary therapy. American Journal of Hematology, 2017, 92, 1280-1286.	4.1	34
23	Prognostic significance of serum beta-2 microglobulin in patients with diffuse large B-cell lymphoma in the rituximab era. Oncotarget, 2016, 7, 76934-76943.	1.8	33
24	Comprehensive analysis of peripheral T-cell and natural killer/T-cell lymphoma in Asian patients: A multinational, multicenter, prospective registry study in Asia. The Lancet Regional Health - Western Pacific, 2021, 10, 100126.	2.9	30
25	Prognostic Significance of Absolute Lymphocyte Count/Absolute Monocyte Count Ratio at Diagnosis in Patients with Multiple Myeloma. Korean Journal of Pathology, 2013, 47, 526.	1.3	27
26	RGS1 expression is associated with poor prognosis in multiple myeloma. Journal of Clinical Pathology, 2017, 70, 202-207.	2.0	27
27	Role of whole-body MRI for treatment response assessment in multiple myeloma: comparison between clinical response and imaging response. Cancer Imaging, 2020, 20, 14.	2.8	27
28	Intestinal Diffuse Large B-Cell Lymphoma: An Evaluation of Different Staging Systems. Journal of Korean Medical Science, 2014, 29, 53.	2.5	26
29	Clinical features and outcomes in patients with human immunodeficiency virus-negative, multicentric Castleman's disease: a single medical center experience. Blood Research, 2014, 49, 253.	1.3	26
30	Efficacy of Brentuximab Vedotin in Relapsed or Refractory High-CD30â€“Expressing Non-Hodgkin Lymphomas: Results of a Multicenter, Open-Labeled Phase II Trial. Cancer Research and Treatment, 2020, 52, 374-387.	3.0	26
31	Pharmacodynamic Effects and Immune Correlates of Response to the CD20/CD3 Bispecific Antibody Mosunetuzumab in Relapsed or Refractory Non-Hodgkin Lymphoma. Blood, 2019, 134, 1585-1585.	1.4	26
32	Usefulness of Interim FDG-PET After Induction Chemotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck Receiving Sequential Induction Chemotherapy Followed by Concurrent Chemoradiotherapy. International Journal of Radiation Oncology Biology Physics, 2011, 81, 118-125.	0.8	25
33	Serum beta-2 microglobulin as a prognostic biomarker in patients with mantle cell lymphoma. Hematological Oncology, 2016, 34, 22-27.	1.7	25
34	Sunitinib as a second-line therapy for advanced GISTs after failure of imatinib: relationship between efficacy and tumor genotype in Korean patients. Investigational New Drugs, 2012, 30, 819-827.	2.6	24
35	A Randomized Phase III Trial on the Role of Esophagectomy in Complete Responders to Preoperative Chemoradiotherapy for Esophageal Squamous Cell Carcinoma (ESOPRESSO). Anticancer Research, 2019, 39, 5123-5133.	1.1	23
36	Efficacy and safety of prophylactic high-dose MTX in high-risk DLBCL: a treatment intentâ€“based analysis. Blood Advances, 2021, 5, 2142-2152.	5.2	23

#	Article	IF	Citations
37	Subcutaneous Mosunetuzumab in Relapsed or Refractory B-Cell Lymphoma: Promising Safety and Encouraging Efficacy in Dose Escalation Cohorts. Blood, 2020, 136, 45-46.	1.4	22
38	Primary Histiocytic Sarcoma of the Central Nervous System. Cancer Research and Treatment, 2015, 47, 322-328.	3.0	21
39	The survivin suppressant YM155 potentiates chemosensitivity to gemcitabine in the human pancreatic cancer cell line MiaPaCa-2. Anticancer Research, 2012, 32, 1681-8.	1.1	21
40	GLUT1 as a Prognostic Factor for Classical Hodgkinâ€™s Lymphoma: Correlation with PD-L1 and PD-L2 Expression. Journal of Pathology and Translational Medicine, 2017, 51, 152-158.	1.1	20
41	Primary central nervous system lymphoma: a new prognostic model for patients with diffuse large B-cell histology. Blood Research, 2017, 52, 285.	1.3	19
42	Systemic HD-MTX for CNS prophylaxis in high-risk DLBCL patients: a prospectively collected, single-center cohort analysis. International Journal of Hematology, 2019, 110, 86-94.	1.6	19
43	The Efficacy of JAK2 Inhibitor in Heavily Pretreated Classical Hodgkin Lymphoma: A Prospective Pilot Study of Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma and Primary Mediastinal Large B-Cell Lymphoma. Blood, 2016, 128, 1820-1820.	1.4	19
44	Pretreatment whole blood Epstein-Barr virus-DNA is a significant prognostic marker in patients with Hodgkin lymphoma. Annals of Hematology, 2016, 95, 801-808.	1.8	18
45	Sexual problems in male vs. female non-Hodgkin lymphoma survivors: prevalence, correlates, and associations with health-related quality of life. Annals of Hematology, 2017, 96, 739-747.	1.8	18
46	Epsteinâ€Barr virus positivity is associated with angiogenesis in, and poorer survival of, patients receiving standard treatment for classical Hodgkin's lymphoma. Hematological Oncology, 2018, 36, 182-188.	1.7	18
47	Ruxolitinib shows activity against Hodgkin lymphoma but not primary mediastinal large B-cell lymphoma. BMC Cancer, 2019, 19, 1080.	2.6	17
48	Efficacy of the novel CDK7 inhibitor QS1189 in mantle cell lymphoma. Scientific Reports, 2019, 9, 7193.	3.3	17
49	Treatment of mantle cell lymphoma in Asia: a consensus paper from the Asian Lymphoma Study Group. Journal of Hematology and Oncology, 2020, 13, 21.	17.0	17
50	Prediction and prevention of central nervous system relapse in patients with extranodal natural killer/T-cell lymphoma. Blood, 2020, 136, 2548-2556.	1.4	17
51	The clinical outcomes of rituximab biosimilar CT-P10 (Truxima^{Â®}) with CHOP as first-line treatment for patients with diffuse large B-cell lymphoma: real-world experience. Leukemia and Lymphoma, 2020, 61, 1575-1583.	1.3	17
52	FDG-PET as a Potential Tool for Selecting Patients with Advanced Nonâ€“Small Cell Lung Cancer Who May Be Spared Maintenance Therapy after First-Line Chemotherapy. Clinical Cancer Research, 2011, 17, 5093-5100.	7.0	16
53	Prognostic value of immunohistochemical algorithms in gastrointestinal diffuse large B-cell lymphoma. Blood Research, 2013, 48, 266.	1.3	16
54	LGALS3 as a prognostic factor for classical Hodgkinâ€™s lymphoma. Modern Pathology, 2014, 27, 1338-1344.	5.5	16

#	Article	IF	Citations
55	The absolute lymphocyte to monocyte ratio is associated with poor prognosis in classical Hodgkin lymphoma patients younger than 60â€‰years of age. Hematological Oncology, 2015, 33, 133-140.	1.7	16
56	Bendamustine plus rituximab for relapsed or refractory diffuse large B cell lymphoma: a multicenter retrospective analysis. Annals of Hematology, 2018, 97, 1437-1443.	1.8	16
57	First-Line Treatment for Primary Breast Diffuse Large B-Cell Lymphoma Using Immunochemotherapy and Central Nervous System Prophylaxis: A Multicenter Phase 2 Trial. Cancers, 2020, 12, 2192.	3.7	16
58	The role of frontline autologous stem cell transplantation for primary plasma cell leukemia: a retrospective multicenter study (KMM160). Oncotarget, 2017, 8, 79517-79526.	1.8	16
59	Intraocular lymphoma in Korea: the Consortium for Improving Survival of Lymphoma (CISL) study. Blood Research, 2015, 50, 242.	1.3	15
60	Interim 18F-FGD PET/CT may not predict the outcome in primary central nervous system lymphoma patients treated with sequential treatment with methotrexate and cytarabine. Annals of Hematology, 2017, 96, 1509-1515.	1.8	15
61	Improved Efficacy of Tafasitamab plus Lenalidomide versus Systemic Therapies for Relapsed/Refractory DLBCL: RE-MIND2, an Observational Retrospective Matched Cohort Study. Clinical Cancer Research, 2022, 28, 4003-4017.	7.0	15
62	Treatment of primary testicular diffuse large B cell lymphoma without prophylactic intrathecal chemotherapy: a single center experience. Blood Research, 2014, 49, 170.	1.3	14
63	Highly elevated serum lactate dehydrogenase is associated with central nervous system relapse in patients with diffuse large B-cell lymphoma: Results of a multicenter prospective cohort study. Oncotarget, 2016, 7, 72033-72043.	1.8	14
64	A new extranodal scoring system based on the prognostically relevant extranodal sites in diffuse large B-cell lymphoma, not otherwise specified treated with chemoimmunotherapy. Annals of Hematology, 2016, 95, 1249-1258.	1.8	13
65	Methotrexate elimination and toxicity: MTHFR 677C>T polymorphism in patients with primary CNS lymphoma treated with highâ€dose methotrexate. Hematological Oncology, 2017, 35, 504-509.	1.7	13
66	The cell-of-origin classification of diffuse large B cell lymphoma in a Korean population by the Lymph2Cx assay and its correlation with immunohistochemical algorithms. Annals of Hematology, 2018, 97, 2363-2372.	1.8	13
67	Prognostic factors for relapse and survival among patients with ocular adnexal lymphoma: validation of the eighth edition of the American Joint Committee on Cancer (AJCC) TNM classification. British Journal of Ophthalmology, 2021, 105, 279-284.	3.9	13
68	Open-label, single arm, multicenter phase II study of VIDL induction chemotherapy followed by upfront autologous stem cell transplantation in patients with advanced stage extranodal NK/T-cell lymphoma. Bone Marrow Transplantation, 2021, 56, 1205-1208.	2.4	13
69	The immune checkpoint molecule V-set Ig domain-containing 4 is an independent prognostic factor for multiple myeloma. Oncotarget, 2017, 8, 58122-58132.	1.8	13
70	Phase II study of Râ€“CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma: consortium for improving survival of lymphoma (CISL) study. Cancer Communications, 2019, 39, 1-10.	9.2	12
71	Pralatrexate in patients with recurrent or refractory peripheral T-cell lymphomas: a multicenter retrospective analysis. Scientific Reports, 2019, 9, 20302.	3.3	12
72	Prognostic value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in newly diagnosed multiple myeloma: a systematic review and meta-analysis. European Radiology, 2021, 31, 152-162.	4.5	12

#	Article	IF	Citations
73	Autologous EBV-specific T cell treatment results in sustained responses in patients with advanced extranodal NK/T lymphoma: results of a multicenter study. Annals of Hematology, 2021, 100, 2529-2539.	1.8	12
74	Improved prognostic stratification using NCCN- and GELTAMO-international prognostic index in patients with diffuse large B-cell lymphoma. Oncotarget, 2017, 8, 92171-92182.	1.8	12
75	Prognostic effect of Ki-67 expression in rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone-treated diffuse large B-cell lymphoma is limited to non-germinal center B-cell-like subtype in late-elderly patients. Leukemia and Lymphoma, 2015, 56, 2630-2636.	1.3	11
76	18F-FDG PET in Patients with Primary Systemic Anaplastic Large Cell Lymphoma: Differential Features According to Expression of Anaplastic Lymphoma Kinase. Nuclear Medicine and Molecular Imaging, 2013, 47, 249-256.	1.0	10
77	Bone marrow involvement is not associated with the clinical outcomes of gastric mucosa-associated lymphoid tissue lymphoma. Scandinavian Journal of Gastroenterology, 2016, 51, 942-948.	1.5	10
78	Results of a phase II study of vorinostat in combination with intravenous fludarabine, mitoxantrone, and dexamethasone in patients with relapsed or refractory mantle cell lymphoma: an interim analysis. Cancer Chemotherapy and Pharmacology, 2016, 77, 865-873.	2.3	10
79	Thiotepa, busulfan, and cyclophosphamide or busulfan, cyclophosphamide, and etoposide high-dose chemotherapy followed by autologous stem cell transplantation for consolidation of primary central nervous system lymphoma. Annals of Hematology, 2019, 98, 1657-1664.	1.8	10
80	Treatment Outcomes of Rituximab Plus Hyper-CVAD in Korean Patients with Sporadic Burkitt or Burkitt-like Lymphoma: Results of a Multicenter Analysis. Cancer Research and Treatment, 2015, 47, 173-181.	3.0	10
81	Expression of CD99 in Multiple Myeloma: A Clinicopathologic and Immunohistochemical Study of 170 Cases. Korean Journal of Pathology, 2014, 48, 209.	1.3	9
82	Platelet to lymphocyte ratio (PLR) retains independent prognostic significance in advanced stage marginal zone lymphoma patients treated with rituximab, cyclophosphamide, vincristine, and prednisone combination chemotherapy (R-CVP): Consortium for Improving Survival of Lymphoma trial. Blood Research, 2017, 52, 200.	1.3	9
83	Pomalidomide, cyclophosphamide, and dexamethasone for elderly patients with relapsed and refractory multiple myeloma: A study of the Korean Multiple Myeloma Working Party (KMMWPâ€164) Tj ETQq1 1 0.784314 rgBT /Over	1.7	9
84	Engagement of CD99 Reduces AP-1 Activity by Inducing BATF in the Human Multiple Myeloma Cell Line RPMI8226. Immune Network, 2015, 15, 260.	3.6	8
85	<scp>TCL</scp>1 expression predicts overall survival in patients with mantle cell lymphoma. European Journal of Haematology, 2015, 95, 583-594.	2.2	8
86	Efficacy and Survival Outcome Associated with the Use of Novel Agents and Autologous Stem Cell Transplantation in Cases of Immunoglobulin D Multiple Myeloma in Korea. Acta Haematologica, 2018, 139, 185-192.	1.4	8
87	Superiority of Epstein-Barr Virus DNA in the Plasma Over Whole Blood for Prognostication of Extranodal NK/T Cell Lymphoma. Frontiers in Oncology, 2020, 10, 594692.	2.8	8
88	A phase II study of ibrutinib in combination with rituximab-cyclophosphamide-doxorubicin hydrochloride-vincristine sulfate-prednisone therapy in Epstein-Barr virus-positive, diffuse large B cell lymphoma (54179060LYM2003: IVORY study): results of the final analysis. Annals of Hematology, 2020, 99, 1283-1291.	1.8	8
89	Risk Stratification Using Multivariable Fractional Polynomials in Diffuse Large B-Cell Lymphoma. Frontiers in Oncology, 2020, 10, 329.	2.8	8
90	A Phase 1 Study of the Combination of MG4101, Ex Vivo-Expanded Allogeneic NK Cells and Rituximab for Relapsed or Refractory Non-Hodgkin Lymphoma. Blood, 2020, 136, 14-15.	1.4	8

#	Article	IF	Citations
91	Tafasitamab Plus Lenalidomide Versus Pola-BR, R2, and CAR T: Comparing Outcomes from RE-MIND2, an Observational, Retrospective Cohort Study in Relapsed/Refractory Diffuse Large B-Cell Lymphoma. Blood, 2021, 138, 183-183.	1.4	8
92	Prognostic factors for re-mobilization using plerixafor and granulocyte colony-stimulating factor (G-CSF) in patients with malignant lymphoma or multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy: the Korean multicenter retrospective study. Annals of Hematology, 2016, 95, 603-611.	1.8	7
93	Induction chemotherapy followed by up-front autologous stem cell transplantation may have a survival benefit in high-risk diffuse large B-cell lymphoma patients. Experimental Hematology, 2016, 44, 3-13.	0.4	7
94	Electrophysiologic features of POEMS syndrome compared with MGUSâ€related neuropathy. Muscle and Nerve, 2017, 56, E73-E77.	2.2	7
95	Clinical characteristics, treatment, and outcome of primary rectal lymphoma: a single center experience of 16 patients. Blood Research, 2017, 52, 125.	1.3	7
96	Effect of an Arm Traction Device on Image Quality and Radiation Exposure during Neck CT: A Prospective Study. American Journal of Neuroradiology, 2018, 39, 151-155.	2.4	7
97	A Case of Type II Enteropathy-Associated T-Cell Lymphoma with Epstein-Barr Virus Positivity. Korean Journal of Pathology, 2014, 48, 426-429.	1.3	6
98	Bendamustine in heavily pre-treated multiple myeloma patients: Results of a retrospective analysis from the Korean Multiple Myeloma Working Party. Blood Research, 2016, 51, 193.	1.3	6
99	Treatment outcomes of dose-attenuated CHOP chemotherapy in elderly patients with peripheral T cell lymphoma. Blood Research, 2017, 52, 270.	1.3	6
100	Feasibility of abbreviated cycles of immunochemotherapy for completely resected limited-stage CD20+ diffuse large B-cell lymphoma (CISL 12-09). Oncotarget, 2017, 8, 13367-13374.	1.8	6
101	Body Cavityâ€"Based Lymphoma in a Country with Low Human Immunodeficiency Virus Prevalence: A Series of 17 Cases from the Consortium for Improving Survival of Lymphoma. Cancer Research and Treatment, 2019, 51, 1302-1312.	3.0	6
102	BCL2 super-expressor diffuse large B-cell lymphoma: a distinct subgroup associated with poor prognosis. Modern Pathology, 2022, 35, 480-488.	5.5	6
103	S-1 plus cisplatin: another option in the treatment of advanced head and neck cancer?. Expert Review of Anticancer Therapy, 2010, 10, 659-662.	2.4	5
104	Advanced POEMS syndrome treated with high-dose melphalan followed by autologous blood stem cell transplantation: a single-center experience. Blood Research, 2014, 49, 42.	1.3	5
105	Recurrence patterns of mucose-associated lymphoid tissue lymphoma after definitive radiation treatment: A single center experience. Hematology, 2016, 21, 542-548.	1.5	5
106	Efficacy and toxicity of the combination chemotherapy of thalidomide, alkylating agent, and steroid for relapsed/refractory myeloma patients: a report from the Korean Multiple Myeloma Working Party (KMMWP) retrospective study. Cancer Medicine, 2017, 6, 100-108.	2.8	5
107	Phase I study of CKD-581, a pan-histone deacetylase inhibitor, in patients with lymphoma or multiple myeloma refractory to standard therapy. Investigational New Drugs, 2018, 36, 877-885.	2.6	5
108	Treating synchronous bilateral ocular adnexal marginal zone lymphoma: the consortium for improving survival of lymphoma study. Annals of Hematology, 2018, 97, 1851-1857.	1.8	5

#	Article	IF	Citations
109	Distinct clinical characteristics at diagnosis in patients with late relapses compared with early relapses of diffuse large B-cell lymphoma treated with R-CHOP. Leukemia and Lymphoma, 2020, 61, 1119-1125.	1.3	5
110	The effectiveness and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma in real-world clinical practice: a study of the Korean Multiple Myeloma Working Party (KMMWP-151 study). Annals of Hematology, 2020, 99, 309-319.	1.8	5
111	Clinical, Laboratory, and Bone Marrow Findings of 31 Patients With WaldenstrÃ¶m Macroglobulinemia. Annals of Laboratory Medicine, 2020, 40, 193-200.	2.5	5
112	Quantitative analysis of tumor-specific BCL2 expression in DLBCL: refinement of prognostic relevance of BCL2. Scientific Reports, 2020, 10, 10680.	3.3	5
113	Assessment of naive indolent lymphoma using whole-body diffusion-weighted imaging and T2-weighted MRI: results of a prospective study in 30 patients. Cancer Imaging, 2021, 21, 5.	2.8	5
114	Reappraisal of the prognostic value of Epstein-Barr virus status in monomorphic post-transplantation lymphoproliferative disordersâ€“diffuse large B-cell lymphoma. Scientific Reports, 2021, 11, 2880.	3.3	5
115	Upward trend in follicular lymphoma among the Korean population: 10-year experience at a large tertiary institution. Journal of Pathology and Translational Medicine, 2021, 55, 330-337.	1.1	5
116	Breast implantâ€“associated anaplastic large cell lymphoma: the first South Korean case. Journal of Pathology and Translational Medicine, 2020, 54, 432-434.	1.1	5
117	A phase I/II study of golidocitinib, a selective JAK1 inhibitor, in refractory or relapsed peripheral T-cell lymphoma.. Journal of Clinical Oncology, 2022, 40, 7563-7563.	1.6	5
118	Clinical Factors Associated with Response or Survival after Chemotherapy in Patients with WaldenstrÃ¶m Macroglobulinemia in Korea. BioMed Research International, 2014, 2014, 1-7.	1.9	4
119	Insulinâ€like growth factorâ€1 receptor is associated with better prognosis in classical Hodgkin's lymphoma: Correlation with <scp>MET</scp> expression. International Journal of Experimental Pathology, 2015, 96, 232-239.	1.3	4
120	The clinical impact of thalidomide maintenance after autologous stem cell transplantation in patients with newly diagnosed multiple myeloma in real clinical practice of Korea. Annals of Hematology, 2016, 95, 911-919.	1.8	4
121	Pneumocystispneumonia versus rituximab-induced interstitial lung disease in lymphoma patients receiving rituximab-containing chemotherapy. Medical Mycology, 2016, 55, myw095.	0.7	4
122	A phase II study of oxaliplatin and prednisone for patients with relapsed or refractory marginal zone lymphoma: Consortium for Improving Survival of Lymphoma trial. Leukemia and Lymphoma, 2016, 57, 1406-1412.	1.3	4
123	Sequential heart and autologous stem cell transplantation for light-chain cardiac amyloidosis. Blood Research, 2017, 52, 221.	1.3	4
124	A prognostic index for extranodal marginalâ€zone lymphoma based on the mucosaâ€associated lymphoid tissue International Prognostic Index and serum Î²2â€microglobulin levels. British Journal of Haematology, 2021, 193, 307-315.	2.5	4
125	Realâ€world outcomes of ibrutinib therapy in Korean patients with relapsed or refractory mantle cell lymphoma: a multicenter, retrospective analysis. Cancer Communications, 2021, 41, 275-278.	9.2	4
126	The limited role of comprehensive staging workâ€up in ocular adnexal extranodal marginal zone lymphoma of mucosaâ€associated lymphoid tissue type (MALToma) with excellent prognosis. British Journal of Haematology, 2021, 193, 848-851.	2.5	4

#	Article	IF	Citations
127	Occurrence of sarcoidosis after chemotherapy for non-Hodgkin lymphoma. Korean Journal of Internal Medicine, 2016, 31, 605-607.	1.7	4
128	Pegfilgrastim Prophylaxis is Effective in the Prevention of Febrile Neutropenia and Reduces Mortality in Patients Aged â‰¥75 Years with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: A Prospective Cohort Study. Cancer Research and Treatment, 2021, , .	3.0	4
129	Expression of JL1 in Burkitt lymphoma is associated with improved overall survival. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2011, 459, 353-359.	2.8	3
130	Abbreviated chemotherapy for limited-stage diffuse large B-cell lymphoma after complete resection. Blood Research, 2014, 49, 115.	1.3	3
131	Is there role of additional chemotherapy after definitive local treatment for stage I/II marginal zone lymphoma?: Consortium for Improving Survival of Lymphoma (CISL) study. International Journal of Hematology, 2015, 102, 420-425.	1.6	3
132	POEMS Syndrome: Bone Marrow, Laboratory, and Clinical Findings in 24 Korean Patients. Annals of Laboratory Medicine, 2019, 39, 561-565.	2.5	3
133	A phase II study of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin (ESHAOx) for patients with refractory or relapsed Hodgkinâ€™s lymphoma. Annals of Hematology, 2020, 99, 255-264.	1.8	3
134	Long-term follow-up of abbreviated R-CHOP chemoimmunotherapy for completely resected limited-stage diffuse large B cell lymphoma (CISL 12-09). Annals of Hematology, 2020, 99, 2831-2836.	1.8	3
135	Treatment with intravenous busulfan, melphalan, and etoposide followed by autologous stem cell transplantation in patients with nonâ€Hodgkin's lymphoma: a multicenter study from the consortium for improving survival of lymphoma. Transplant International, 2020, 33, 1211-1219.	1.6	3
136	Clinical impact of frailty on treatment outcomes of elderly patients with relapsed and/or refractory multiple myeloma treated with lenalidomide plus dexamethasone. International Journal of Hematology, 2021, 113, 81-91.	1.6	3
137	An Individualized Risk Mitigation Approach for Safety: Experience from the Mosunetuzumab (CD20/CD3) Tj ETQq1 1 0.784314 rgBT /Ov 4728-4728.	1.4	3
138	Diffuse Large B-Cell Lymphoma with Involvement of the Breast and Testis in a Male Patient. Cancer Research and Treatment, 2015, 47, 539-543.	3.0	3
139	Asian Multinational Phase II Study of Darinaparsin in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma. Blood, 2021, 138, 1376-1376.	1.4	3
140	Multicenter retrospective analysis of patients with chronic lymphocytic leukemia in Korea. Blood Research, 2021, , .	1.3	3
141	A phase I study of S-1 treatment with a 3Âweek schedule in advanced biliary cancer patients with or without hepatic dysfunction. Investigational New Drugs, 2011, 29, 332-339.	2.6	2
142	Clinicopathological and prognostic significance of BCL2, BCL6, MYC, and IRF4 copy number gains and translocations in follicular lymphoma: a study by FISH analysis. Leukemia and Lymphoma, 2020, 61, 3342-3350.	1.3	2
143	Assessment of NK Cell Activity Based on NK Cell-Specific Receptor Synergy in Peripheral Blood Mononuclear Cells and Whole Blood. International Journal of Molecular Sciences, 2020, 21, 8112.	4.1	2
144	VPDL Chemotherapy for T-cell Lymphoblastic Lymphoma (T-LBL) in Adults: Comparison with Upfront Autologous Stem Cell Transplantation in a Single Center. The Korean Journal of Hematology, 2008, 43, 138.	0.7	2

#	Article	IF	Citations
145	The prognostic impact of inflammatory factors in patients with multiple myeloma treated with thalidomide in Korea. Korean Journal of Internal Medicine, 2015, 30, 675-683.	1.7	2
146	TEMPO: A Phase 2, Randomized, Open-Label, 2-Arm Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Subjects with Indolent Non Hodgkin Lymphoma (iNHL). Blood, 2021, 138, 3545-3545.	1.4	2
147	Distinct genetic alterations in Burkitt-like lymphoma with 11q aberration and Burkitt lymphoma: a novel case report of composite lymphoma. Haematologica, 2022, 107, 1999-2003.	3.5	2
148	Relapse with plasmacytoma after upfront autologous stem cell transplantation in multiple myeloma. Annals of Hematology, 2022, 101, 1217-1226.	1.8	2
149	Outcomes in Refractory Diffuse Large B-Cell Lymphoma: Results from Two Prospective Korean Cohorts. Cancer Research and Treatment, 2023, 55, 325-333.	3.0	2
150	Case series of precursor B-cell lymphoblastic lymphoma. Blood Research, 2014, 49, 270.	1.3	1
151	Prognostic Impact of Age at the Time of Diagnosis in Korean Patients with Diffuse Large B-cell Lymphoma in the Rituximab Era: A Single Institution Study. Cancer Research and Treatment, 2021, 53, 270-278.	3.0	1
152	Immune Checkpoint Programmed Cell Death Protein-1 (PD-1) Expression on Bone Marrow T Cell Subsets in Patients With Plasma Cell Myeloma. Annals of Laboratory Medicine, 2021, 41, 259-267.	2.5	1
153	Cutaneous T-cell lymphoma in Asian patients: a multinational, multicenter, prospective registry study in Asia. International Journal of Hematology, 2021, 114, 355-362.	1.6	1
154	Multicenter, phase II study of response-adapted lenalidomide-based therapy for transplant-ineligible patients with newly diagnosed multiple myeloma without high-risk features. Current Problems in Cancer, 2021, 46, 100788.	2.0	1
155	Central Nervous System Relapse in Patients with Peripheral T-Cell Lymphoma. Blood, 2018, 132, 5346-5346.	1.4	1
156	Prognostic Impact of Mid-Treatment PET in Patients with Diffuse Large B-Cell Lymphoma Who Achieved Metabolic CR at Post-Treatment PET. Blood, 2009, 114, 3949-3949.	1.4	1
157	Autologous Stem Cell Transplantation with Thiotepa, Busulfan, and Cyclophosphamide Conditioning in Patients with Primary Central Nervous System Lymphoma: A Remarkable Outcome Form Single-Center Experience. Blood, 2016, 128, 3462-3462.	1.4	1
158	PROGNOSTIC SIGNIFICANCE of CD68 EXPRESSION for Korean PATIENTS with HODGKIN'S LYMPHOMA. Blood, 2010, 116, 3888-3888.	1.4	1
159	Prognostic Value of Positron Emission Tomography- Computed Tomography in Patients with Marginal Zone Lymphoma. Blood, 2012, 120, 5084-5084.	1.4	1
160	A Phase 1 Dose Escalation Study of Dual PI3K and DNA PK Inhibitor, BR101801 in Adult Patients with Advanced Hematologic Malignancies. Blood, 2021, 138, 3562-3562.	1.4	1
161	CAMMA 3: A multicenter phase Ib trial evaluating the safety, pharmacokinetics, and activity of subcutaneous cevostamab monotherapy in patients with relapsed or refractory multiple myeloma.. Journal of Clinical Oncology, 2022, 40, TPS8070-TPS8070.	1.6	1
162	Pharmacokinetic and pharmacodynamic study of lenograstim for hematopoietic stem cell mobilization: a prospective randomized study for optimal apheresis. Transfusion, 2019, 59, 1781-1788.	1.6	0

#	Article	IF	Citations
163	Feasibility of reduced-dose CT of the head and neck with iterative reconstruction: a phantom and prospective clinical study. Acta Radiologica, 2019, 60, 1457-1464.	1.1	0
164	JL1 Antigen Expression on Bone Marrow Lymphoma Cells from Patients With Non-Hodgkin Lymphoma. Annals of Laboratory Medicine, 2020, 40, 1-6.	2.5	0
165	Timing of G-CSF Injection for Effective Autologous Stem Cell Collection. Blood, 2008, 112, 4439-4439.	1.4	0
166	SIGNIFICANCE of ABSOLUTE LYMPHOCYTE COUNT at RELAPSE as a PROGNOSTIC FACTOR in PATIENTS with T-CELL NON-HODGKIN'S LYMPHOMA.. Blood, 2009, 114, 2939-2939.	1.4	0
167	Comparison of Survival and Clinical Features In Different Age Cohorts of Patients with Multiple Myeloma: A Single Center Experience. Blood, 2010, 116, 4997-4997.	1.4	0
168	Yttrium-90-Ibritumomab Tiuxetan and BuCyE High-Dose Chemotherapy Compared with BuCyE Alone As Conditioning Regimen in Patients with B-Cell Non-Hodgkin Lymphoma: IPI Matched Case Control Study At a Single Center,. Blood, 2011, 118, 3703-3703.	1.4	0
169	The Clinical Utility of FDG PET-CT in Evaluation of Bone Marrow Involvement by Diffuse Large B Cell Lymphoma. Blood, 2011, 118, 2661-2661.	1.4	0
170	Associations of Methylene Tetrahydrofolate Reductase Polymorphism and Methotrexate-Related Toxicities in Korean Treated for Malignant Lymphoma. Blood, 2011, 118, 1607-1607.	1.4	0
171	Remobilization with High Dose Methotrexate and Cytarabine in Patients with Non-Hodgkin Lymphoma and Multiple Myeloma Previously Failing Mobilization with Chemotherapy and Cytokine Treatment. Blood, 2011, 118, 4402-4402.	1.4	0
172	Clinical Significance of Immunoglobulin Isotype Switching in Patients with Multiple Myeloma. Blood, 2012, 120, 4980-4980.	1.4	0
173	Prospective Cohort Study with Risk-Adapted Central Nervous System (CNS) Evaluation in Diffuse Large B-Cell Lymphoma Patients Treated with Rituximab-CHOP: Analysis of Incidence and Risk Factors for Secondary CNS Involvement.. Blood, 2012, 120, 2683-2683.	1.4	0
174	Peripheral Blood Hematopoietic Progenitor Cell (HPC) Counts At Autologous Stem Cell Collection (ASCC) Are Associated with Prognosis in Multiple Myeloma. Blood, 2012, 120, 4412-4412.	1.4	0
175	Prognostic Significance Of Positron Emission Tomography-Computed Tomography In Patients With Marginal Zone Lymphoma. Blood, 2013, 122, 4324-4324.	1.4	0
176	Prognostic Impact Of Beta-2 Microglobulin In Patients With Non-Gastric Marginal Zone Lymphoma. Blood, 2013, 122, 4297-4297.	1.4	0
177	The Clinical Impact of Thalidomide Maintenance on Progression Free Survival and Postrelapse Survival after Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple myeloma. Blood, 2014, 124, 3975-3975.	1.4	0
178	Proposal of New Prognostic Index for Patients with Diffuse Large B-Cell Lymphoma in the Rituximab Era. Blood, 2014, 124, 1668-1668.	1.4	0
179	The Prognostic Impact of Inflammatory Factors for Survival in Patients with Newly Diagnosed Multiple Myeloma Who Were Treated with Thalidomide Containing Induction Chemotherapy Underwent Autologous Stem Cell Transplantation. Blood, 2014, 124, 5896-5896.	1.4	0
180	The Outcomes of Korean Patients with Primary Plasma Cell Leukemia: Analysis of Korean Multiple Myeloma Working Party (KMM160). Blood, 2016, 128, 4445-4445.	1.4	0

#	Article	IF	Citations
181	A Phase II Trial of Bendamustine, Carboplatin and Dexamethasone (BCD) for Refractory or Relapsed Peripheral T-Cell Lymphoma (BENCART): A Consortium for Improving Survival of Lymphoma (CISL) Trial. Blood, 2016, 128, 1823-1823.	1.4	0
182	Bortezomib-Melphalan-Prednisone (VMP) Versus MP As Initial Treatment for Patients Older Than 75 Years with Newly Diagnosed Multiple Myeloma. Blood, 2016, 128, 5683-5683.	1.4	0
183	Prognostic Value of Serum Beta-2 Microglobulin during and after Completing Chemotherapy in Marginal Zone Lymphoma. Blood, 2018, 132, 5335-5335.	1.4	0
184	Central Nervous System Relapse in Patients with Extranodal NK/T-Cell Lymphoma, Nasal Type. Blood, 2018, 132, 1634-1634.	1.4	0
185	The Predictors and Prevention of the Central Nervous System Relapse in Patients with Extranodal NK/T Cell Lymphoma, Nasal Type. Blood, 2019, 134, 2847-2847.	1.4	0
186	Comparison of clinical and laboratory characteristics of nonsecretory multiple myeloma and secretory multiple myeloma in a tertiary care hospital. International Journal of Laboratory Hematology, 2022, , .	1.3	0
187	Characteristics and clinical outcome of high-risk multiple myeloma patients in Korea (KMM 1805). International Journal of Hematology, 2022, , 1.	1.6	0
188	Clinical outcomes of early-progressed follicular lymphoma in Korea: a multicenter, retrospective analysis. Archives of Medical Science, 0, , .	0.9	0
189	Abstract CT127: Trial in progress: A phase II, open-label, multicenter study of capivasertib, a potent, oral pan-AKT inhibitor in patients with relapsed or refractory B-cell non-hodgkin lymphoma (CAPITAL). Cancer Research, 2022, 82, CT127-CT127.	0.9	0
190	Subgroup analysis in RE-MIND2, an observational, retrospective cohort study of tafasitamab plus lenalidomide versus systemic therapies in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL).. Journal of Clinical Oncology, 2022, 40, 7560-7560.	1.6	0